차세대 시퀀싱 시장 규모, 점유율, 동향 및 예측 : 시퀀싱 유형, 제품 유형, 기술, 용도, 최종 사용자, 지역별(2026-2034년)

The global next generation sequencing market size was valued at USD 27.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 92.8 Billion by 2034, exhibiting a CAGR of 14.29% from 2026-2034. North America currently dominates the market, holding a market share of over 39.7% in 2025. The market for NGS is expanding rapidly due to ongoing technological advancements, increasing use in clinical applications, escalating demand for bioinformatics tools and data analysis solutions, a rising focus on precision medicine, as well as enhanced research and development efforts.

The next generation sequencing market is growing vigorously on the grounds of advancement in genomic technology and rising personalized medicine demand. Its higher throughput along with cost-effective sequencing has totally changed the application for diagnosis, drug discovery, and precision agriculture. Increased spending in genomics and governmental support towards research initiatives is also expected to add fuel to adoption in academic and clinical space. Along with this, innovations like long-read sequencing and advancements in data analysis tools to augment both accuracy and efficacy of NGS. Moreover, the trend of application towards noninvasive prenatal testing and cancer diagnosis through NGS will further define its growing role in bringing health solutions to new frontiers.

The NGS market in the United States is seeing a significant increase, primarily as a function of extensive government support and a focus on precision medicine. An advanced healthcare infrastructure, combined with the use of genomic technologies in research and clinical practice, is further enhancing the market' presence in the country. In addition, the adoption of next-generation sequencing (NGS) applications in cancer management, increasingly in the areas of tumor profiling and liquid biopsy, is spurring demand for their significant impact on patient outcome improvement. For instance, in September 2024, NeoGenomics, a U.S. based oncology testing service company, unveiled three studies at ESMO Congress 2024 in Barcelona, focusing on the role of ctDNA analysis and NGS in improving early cancer detection and personalized treatment approaches. Furthermore, the U.S. market is benefiting from favorable regulatory policies that support the adoption of NGS-based diagnostic solutions.

NEXT GENERATION SEQUENCING MARKET TRENDS:

Increasing Adoption of NGS in Clinical Applications

The utilization of next generation sequencing (NGS) in clinical applications is fast increasing, altering many aspects of healthcare. From diagnoses to personalized treatment strategies, NGS is revolutionizing clinical practice by providing unprecedented insights into disease genetics. Industry data reveals that 75% of U.S. consumers are eager for healthcare experiences that cater more to their individual needs. In diagnostic testing, NGS offers rapid and complete analysis of genomic variations, enabling the exact diagnosis of rare genetic disorders, cancer mutations, and infectious pathogens. Its function includes prenatal screening, pharmacogenomics, and uncommon illness diagnosis, giving clinicians critical genetic information for personalized patient management. For instance, OmniSeq and LabCorp, the U.S.-based life science company, introduced OmniSeq INSIGHTsm, a next-generation sequencing test designed to advance precision oncology. Additionally, NGS-based genomic profiling is propelling precision medicine initiatives, guiding targeted therapy selection, and hastening the identification of novel medications in clinical trials. As NGS technology improves and becomes more affordable, its integration into clinical workflows. For instance, the U.S.-based company Agilent Technologies Inc. introduced Agilent Sure Select Cancer CGP Assay, based on NGS, for advancing precision oncology. Thus, the increasing focus of industry participants on NGS for precision oncology is expected to boost the next generation sequencing market demand.

Technological Advancements in NGS Technology

Advances in the technology of NGS have moved the field forward, changing the nature of genomic research and its applications across several sectors. In 2023, the size of the genomics market stood at USD 33.9 Billion. Such developments include upgrading of sequencing platforms, chemistry, and ways of data processing. Enhanced sequencing platforms have increased throughput, enabling the capture of larger volumes of sequencing data in less time and at a lower cost. This is positively influencing the next generation sequencing market statistics. Additionally, advancements in sequencing chemistry have made it possible to increase the accuracy of sequencing and the length of reads, thus enabling more complete coverage of the genome and improved detection of genomic variations. Furthermore, recent developments in data analytic techniques and computational methodology have simplified the processing, analysis, and interpretation of NGS data, allowing researchers to extract relevant insights from large genomic datasets more efficiently. Overall, technical advancements in NGS continue to propel the industry forward and increase its applications. For instance, Ultima Genomics and Nvidia partnered to leverage artificial intelligence (AI) across multiple DNA sequencing and analysis stages. Moreover, Ultima's instrument utilizes the Nvidia Clara AI computing platform along with Nvidia A30 GPUs to provide highly accurate secondary and primary analysis to those customers who need to run genomic analyses at scale. Thus, adopting AI and cloud computing is expected to bring novel products and services across the industry.

Growing Demand for Bioinformatics Tools and Data Analysis Solutions

NGS data is maximized with the help of bioinformatics tools and data analysis solutions. The large volumes of genomic data produced by NGS technology are processed, analyzed, and understood with the help of computational resources. Bioinformatics tools cover a wide range of methodologies and software applications that are used in tasks such as read alignment, variant calling, de novo assembly, differential gene expression analysis, and pathway enrichment. The global bioinformatics market size reached USD 12.3 Billion in 2023. Furthermore, data analysis tools provide user-friendly interfaces and integrated procedures that make NGS data processing easier for researchers and clinicians who require advanced computer abilities. Bioinformatics tools and data processing solutions must be constantly created and updated to optimize the insights gained from NGS studies and advance our understanding of genomics, transcriptomics, and epigenomics. For instance, My Intelligent Machines (MIMs) launched its software for drug development in oncology. In another instance, ARUP launched Rio, which is a bioinformatics analytics platform that helps generate faster results for next-generation sequencing tests.

Transformative Approach with Single-Cell Sequencing

Single-cell sequencing is a significant advancement in the area of next generation sequencing (NGS), giving new insights into cellular heterogeneity and functional genomics at the single-cell level. NGS methods, which extract and sequence individual cells, enable detailed investigations into gene expression, DNA mutations, epigenetic changes, and spatial transcriptomics, among other genomic characteristics. This precise understanding of cellular diversity and dynamics has far-reaching consequences in cancer research, immunology, developmental biology, and neurology. According to the NCI, the United States is home to 72 NCI-Designated Cancer Centers across 36 states and the District of Columbia. Single-cell sequencing within the NGS framework has enabled groundbreaking discoveries such as the identification of rare cell populations, the interpretation of cellular pathways throughout development, and a knowledge of the intricacy of the tumor microenvironment. As NGS improvements occur and single-cell sequencing technologies become increasingly widespread, the possibilities they're opening up for understanding the complexity of cellular biology are massive. For instance, Oxford Nanopore Technologies PLC announced a collaboration with 10x Genomics, aimed at streamlining the workflow to enable the sequencing of full-length transcripts in single reads on Oxford Nanopore devices. This collaboration will facilitate single-cell sequencing accessible to any laboratory, thereby increasing efficiency and cost reduction benefits.

NEXT GENERATION SEQUENCING INDUSTRY SEGMENTATION:

Analysis by Sequencing Type :

• Whole Genome Sequencing
• Targeted Resequencing
• Whole Exome Sequencing
• RNA Sequencing
• CHIP Sequencing
• De Novo Sequencing
• Methyl Sequencing
• Others

Targeted resequencing leads the market with around 57.6% of market share in 2025. Targeted resequencing is a prominent part of the next generation sequencing (NGS) industry, driven by its use in diverse academic and therapeutic contexts. Targeted resequencing includes sequencing particular sections of interest within the genome, such as exons, regulatory regions, or disease-associated genes, allowing researchers to concentrate their sequencing efforts on important genomic regions. This technique has various advantages, including enhanced sequencing depth, lower sequencing costs, and more sensitivity for finding genetic variations. Targeted resequencing has also grown in favor of clinical diagnostics due to its capacity to rapidly and accurately assess clinically important genomic areas. Targeted resequencing assays are used by clinical laboratories and healthcare practitioners to diagnose diseases, predict prognoses, and choose treatments, especially in cancer and genetic testing. Another reason for the prominence of targeted resequencing is the presence of numerous companies in the NGS market offering specialized targeted resequencing services. These companies provide custom target enrichment solutions, library preparation kits, sequencing services, and data analysis pipelines tailored to researchers' specific needs. Their offerings encompass a wide range of applications, including cancer panel sequencing, inherited disease testing, pharmacogenomics, and microbial genomics. For instance, Illumina, Inc. has partnered with Nashville Biosciences to enhance drug development through genomics. This multi-year agreement utilizes a biobank of approximately 250,000 de-identified DNA samples from Vanderbilt University Medical Center. The collaboration aims to identify disease targets and improve therapy development, addressing the 90% failure rate in drug discovery.

Analysis by Product Type :

• Instruments
• Reagents and Consumables
• Software and Services

Reagents and consumables lead the market with around 59.7% of market share in 2025. Reagents and consumables are the most often used goods in next-generation sequencing (NGS) workflows, and they play an important role in all stages of the sequencing process, from sample preparation to data analytics. These tools help with several elements of NGS, such as sample collection, DNA or RNA extraction, library preparation, target enrichment, sequencing, and quality control. They make it easier to extract nucleic acids (DNA or RNA) from a variety of sources, including blood, tissues, cells, and environmental materials. Furthermore, most sample preparation kits include chemicals for cell lysis, protein digestion, nucleic acid extraction, and purification. For instance, Lexogen, a transcriptomics, and next-generation sequencing company, introduced the new CORALL RNA-Seq V2 whole transcriptome library prep kit. Whole transcriptome analysis with RNA sequencing (RNA-Seq), as one of the most sophisticated applications of NGS techniques, represents the determination of RNA molecules in a sample while collecting. Additionally, the strategic initiatives taken by the market players also augment the growth of the market. For instance, Merck acquired AmpTec to strengthen Merck's capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments, and diagnostics applicable to COVID-19 and many other diseases.

Analysis by Technology :

• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Single-Molecule Real-Time Sequencing
• Nanopore Sequencing
• Others

Sequencing by synthesis leads the market with around 75.7% of market share in 2025. Sequencing by synthesis has a wide range of applications owing to its high precision, scalability, and interoperability with multiple sequencing technologies. SBS is based on the sequential addition of fluorescently tagged nucleotides to a DNA template strand, followed by imaging to identify the integrated nucleotides. This technique has various advantages, which lead to its widespread use and rising popularity in NGS instrumentation. Furthermore, the SBS technique often provides excellent sequencing accuracy while minimizing error rates per base pair. The use of reversible terminators and error-correction algorithms reduces sequencing mistakes, resulting in trustworthy and precise sequencing findings. Furthermore, SBS is extremely scalable, enabling the sequencing of Millions to Billions of DNA fragments in a single run. This scalability makes SBS ideal for applications requiring high-throughput sequencing, such as whole-genome sequencing, transcriptomics, metagenomics, and population-scale studies. For instance, miR-451 has been identified as a potential prognostic factor in head and neck squamous cell carcinomas (HNSCCs) through miRNA profiling. The clusters of miR-375 and miR-106b-25 are implicated in the development and progression of HNSCCs. Furthermore, miRNAs have shown promise in forensic medicine due to their stability and specificity, making them useful for degraded samples or complex mixes.

Analysis by Application :

• Biomarker and Cancer
• Drug Discovery and Personalized Medicine
• Genetic Screening
• Diagnostics
• Agriculture and Animal Research
• Others

Biomarker and cancer lead the market with around 31.9% of market share in 2025. Biomarkers and cancer dominate the market due to the increased prevalence of cancer and growing public awareness of the advantages of early detection and individualized therapy. Biomarkers are molecular signs present in tissues, blood, or body fluids that can detect cancer, predict disease progression, and guide therapy decisions. NGS technologies provide complete genomic profiling and biomarker discovery, allowing for the detection of genetic mutations, gene expression patterns, and other molecular fingerprints linked to cancer genesis and progression. Furthermore, the expanding global frequency of cancer, as well as increased illness and death rates, have highlighted the necessity of early detection and tailored therapy in improving patient outcomes. NGS-based cancer diagnostics offer several advantages over traditional methods, including higher sensitivity, specificity, and the ability to detect multiple genetic alterations simultaneously. These advancements enable oncologists to tailor treatment strategies based on the unique genomic profiles of individual patients, leading to more effective therapies, reduced side effects, and improved survival rates. For instance, Vela Diagnostics released new next-generation sequencing (NGS)-based panels to detect RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens. The panels are focused (60 genes) and comprehensive (525 genes). The OncoKey SL 60 Plus Panel denotes a target-specific pan-cancer gene panel, while OncoKey SL 525 Plus Panel defines a complete panel for pan-cancer genes.

Analysis by End-User :

• Academic Institutes & Research Centers
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Others

Academic institutes and research centers lead the market with around 58.3% of market share in 2025. Academic institutes and research centers held the majority of the market due to the increased use of NGS technologies in research initiatives. Furthermore, academic institutions and research centers frequently get considerable financing from government agencies, private foundations, and business partners to support genomic research initiatives. This grant enables academics to invest in NGS technology and services for investigating a wide range of biological topics, from fundamental science to translational and clinical research. Furthermore, these universities usually feature well-equipped core facilities and research infrastructure devoted to genomics, molecular biology, and bioinformatics. These facilities are equipped with cutting-edge NGS instruments, laboratory equipment, and computing resources, enabling researchers to undertake cutting-edge genomic investigations and data analysis. Furthermore, the increasing collaboration among interdisciplinary research groups is enabling scientists from diverse backgrounds to collaborate on NGS-driven research projects, facilitating knowledge exchange, resource sharing, and interdisciplinary approaches to address complex scientific questions using NGS technologies. For instance, PacBio, in association with GeneDx, announced collaborative research with the University of Washington to investigate long-read whole-genome sequencing for greater diagnostic yield in neonatal care.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

In 2025, North America accounted for the largest market share of over 39.7%. North America has a clear market lead due to the availability of a technologically sophisticated healthcare research framework in the area, as well as the broad implementation of NGS technology in several clinical laboratories. Furthermore, North America boasts a cutting-edge healthcare infrastructure, which includes prestigious academic institutions, research hospitals, and biotechnology corporations. These institutions have access to cutting-edge NGS equipment, bioinformatics tools, and research funding, allowing them to conduct groundbreaking genomic research and clinical applications. Furthermore, North America has a considerable number of clinical laboratories and genetic testing facilities that use NGS technology to provide diagnostic testing, screening, and genetic counseling services. These facilities provide a comprehensive range of NGS-based assays for hereditary illnesses, cancer diagnostics, prenatal screening, pharmacogenomics, and infectious diseases, which contribute to the wider use of NGS in clinical practice. However, breast cancer is more common among females, while male breast cancer is very rare. For instance, according to the data provided by Breastcancer.org, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, together with 51,400 new cases of non-invasive (in situ) breast cancer.

KEY REGIONAL TAKEAWAYS:

UNITED STATES NEXT GENERATION SEQUENCING MARKET ANALYSIS

In 2025, United States accounted for 92.80% of the market share in North America. The U.S. next-generation sequencing (NGS) market is significantly influenced by the rising incidence of cancer and genetic disorders, driving the demand for advanced diagnostic tools. According to the American Cancer Society, approximately 1,958,310 new invasive cancer cases are expected in the United States in 2023, equivalent to about 5,370 cases daily. This alarming prevalence underscores the critical need for precise and efficient diagnostic technologies like NGS, which are pivotal in identifying mutations and guiding personalized treatment plans. Government support for precision medicine, robust healthcare infrastructure, and substantial investments in genomic research further fuel market growth. Key players continue to innovate, offering cost-effective and high-throughput sequencing platforms, making NGS more accessible for clinical and research applications. The expanding use of NGS in non-invasive prenatal testing (NIPT), rare disease diagnosis, and infectious disease management contributes significantly to its adoption. Favorable regulatory policies, including FDA approvals for NGS-based tests, and the integration of AI for genomic data analysis enhance market prospects. Moreover, the growing trend of direct-to-consumer genetic testing, supported by increasing consumer awareness, adds momentum. The U.S. NGS market thrives on a convergence of technological advancements, public health needs, and a strong focus on precision healthcare solutions.

EUROPE NEXT GENERATION SEQUENCING MARKET ANALYSIS

The next-generation sequencing (NGS) market in Europe is propelled by strong government funding for genomics research and the growing focus on precision medicine. The European Commission estimates that between 27 and 36 Million people in Europe are affected by rare diseases, highlighting the critical need for advanced diagnostic technologies like NGS. These tools enable early and accurate identification of genetic mutations, facilitating tailored treatment approaches for rare and complex conditions. Countries such as the UK, Germany, and France have launched national genome programs to integrate NGS into healthcare, particularly for oncology, rare diseases, and population health management. The European Union's Horizon Europe program and other funding initiatives further support cutting-edge genomic research and technological innovation. Additionally, the increasing adoption of NGS in agriculture and microbiology underscores its expanding applications beyond healthcare. With its robust regulatory framework, the region ensures the safety and quality of NGS-based solutions, instilling trust among healthcare providers. Innovations in bioinformatics and AI-driven genomic analysis enhance accessibility and streamline workflows. Collaboration between academic institutions, biotech firms, and pharmaceutical companies, coupled with rising public awareness of genetic testing, positions Europe as a dynamic market for NGS adoption and growth.

ASIA PACIFIC NEXT GENERATION SEQUENCING MARKET ANALYSIS

The Asia-Pacific next-generation sequencing (NGS) market is driven by increasing healthcare investments and the growing prevalence of non-communicable diseases (NCDs). According to the WHO, 62% of all deaths in the South-East Asia Region are due to NCDs, accounting for approximately 9 Million people annually. This significant burden underscores the need for advanced diagnostic tools like NGS, which play a vital role in detecting genetic predispositions and enabling personalized treatment strategies. Governments across APAC, including China, India, and Japan, are actively supporting genomic initiatives to advance precision medicine and biotechnology. The rising adoption of NGS for non-invasive prenatal testing (NIPT) and infectious disease diagnosis, particularly following recent pandemics, further propels market growth. Additionally, the region benefits from cost-efficient manufacturing, rapid technological advancements by local players, and strategic collaborations with global leaders. Growing public awareness of genetic testing and increasing pharmaceutical R&D expenditure position APAC as a rapidly expanding market for NGS technologies.

LATIN AMERICA NEXT GENERATION SEQUENCING MARKET ANALYSIS

The Latin American next-generation sequencing (NGS) market is driven by increasing healthcare investments, rising awareness of genetic testing, and the growing burden of chronic diseases. In Brazil alone, approximately 928,000 deaths annually are attributed to chronic diseases, according to PubMed Central. This significant health challenge underscores the need for advanced diagnostic tools like NGS, which are essential for early detection and personalized treatment strategies. Countries such as Brazil and Mexico are adopting NGS for applications in oncology, rare disease diagnostics, and infectious disease management. Government efforts to modernize healthcare systems and foster research collaborations with international organizations further propel market growth. Additionally, the affordability and accessibility of sequencing technologies have improved, enabling broader adoption in clinical settings. The region is also leveraging NGS in agricultural genomics and biodiversity research, showcasing its potential beyond healthcare and addressing diverse challenges unique to Latin America.

MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING MARKET ANALYSIS

The Middle East next-generation sequencing (NGS) market is expanding due to rising healthcare investments and the growing burden of chronic diseases. In the UAE, 23% of individuals self-report chronic diseases, with obesity (12.5%), diabetes (4.2%), and asthma/allergies (3.2%) being the most prevalent, according to PubMed Central. These statistics underscore the need for advanced diagnostic tools like NGS to enable early detection and personalized treatment. Countries such as the UAE and Saudi Arabia are adopting NGS for oncology, rare disease diagnostics, and infectious disease management. Government-led genomic initiatives and collaborations with global biotech companies further drive NGS adoption in the region.

COMPETITIVE LANDSCAPE:

The next generation sequencing (NGS) market is highly competitive and features rapid advances in sequencing technologies and applications. Key players concentrate on innovation in sequencing platforms, data analysis tools, and reagents to maintain market leadership. For instance, in January 2023, QIAGEN Digital Insights introduced a significant upgrade to its QIAGEN CLC Genomics Workbench Premium, enabling ultra-fast next NGS analysis. The new LightSpeed technology allows for the analysis of a whole human genome at 34x coverage in just 25 minutes and a whole exome in 90 seconds. This advancement reduces costs to approximately $1 per genome and mere cents for exomes. This advancement streamlines genomic profiling for research and clinical labs, reducing analysis time and improving efficiency. Strategic collaborations between biopharmaceutical companies and research institutions are common, fostering innovation and expanding application areas in oncology, diagnostics, and drug discovery. Furthermore, the integration of artificial intelligence and cloud computing in NGS workflows further accelerates competition, pushing continuous technological advancements.

The report provides a comprehensive analysis of the competitive landscape in the next generation sequencing market with detailed profiles of all major companies, including:

• 10x Genomics Inc.
• Agilent Technologies, Inc.
• BGI Genomics (BGI Group)
• Bio-Rad Laboratories, Inc.
• Eurofins Scientific SE
• F. Hoffmann-La Roche Ltd. (Roche Holding AG)
• Illumina, Inc.
• Macrogen Inc.
• Novogene Co., Ltd.
• QIAGEN N.V.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Next Generation Sequencing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Sequencing Type

• 6.1 Whole Genome Sequencing
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Targeted Resequencing
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Whole Exome Sequencing
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 RNA Sequencing
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 CHIP Sequencing
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 De Novo Sequencing
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Methyl Sequencing
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast
• 6.8 Others
  • 6.8.1 Market Trends
  • 6.8.2 Market Forecast

7 Market Breakup by Product Type

• 7.1 Instruments
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Reagents and Consumables
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Software and Services
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Technology

• 8.1 Sequencing by Synthesis
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Ion Semiconductor Sequencing
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Single-Molecule Real-Time Sequencing
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Nanopore Sequencing
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Application

• 9.1 Biomarker and Cancer
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Drug Discovery and Personalized Medicine
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Genetic Screening
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Diagnostics
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Agriculture and Animal Research
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast
• 9.6 Others
  • 9.6.1 Market Trends
  • 9.6.2 Market Forecast

10 Market Breakup by End-User

• 10.1 Academic Institutes & Research Centers
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Hospitals & Clinics
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Pharmaceutical & Biotechnology Companies
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Others
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 10x Genomics Inc.
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
  • 16.3.2 Agilent Technologies, Inc.
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
    • 16.3.2.4 SWOT Analysis
  • 16.3.3 BGI Genomics (BGI Group)
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
  • 16.3.4 Bio-Rad Laboratories, Inc.
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 Eurofins Scientific SE
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
  • 16.3.6 F. Hoffmann-La Roche Ltd. (Roche Holding AG)
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 Financials
  • 16.3.7 Illumina, Inc.
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 Macrogen Inc.
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
  • 16.3.9 Novogene Co., Ltd.
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
    • 16.3.9.4 SWOT Analysis
  • 16.3.10 QIAGEN N.V.
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
    • 16.3.10.3 Financials
    • 16.3.10.4 SWOT Analysis
  • 16.3.11 Takara Bio Inc.
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
    • 16.3.11.3 Financials
    • 16.3.11.4 SWOT Analysis
  • 16.3.12 Thermo Fisher Scientific Inc.
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio
    • 16.3.12.3 Financials
    • 16.3.12.4 SWOT Analysis